Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 19/20 | 0.53 |
| ▸ | BRAF | P15056 | 18/20 | 0.53 |
| ▸ | FLT1 | P17948 | 2/20 | 0.48 |
| ▸ | KDR | P35968 | 2/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | CSF1R | P07333 | 1/20 | 0.45 |
| ▸ | IGF1R | P08069 | 1/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.45 |
| ▸ | FLT4 | P35916 | 1/20 | 0.45 |
| ▸ | TEK | Q02763 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3878184 | 0.93 | KIT (0.62) | KITBRAFFLT1KDRABL1 | |
| SCHEMBL4042240 | 0.88 | FLT1 (0.44) | KITBRAFFLT1KDRABL1 | |
| SCHEMBL3868747 | 0.88 | KIT (0.60) | KITBRAFFLT1KDRABL1 | |
| SCHEMBL3870092 | 0.88 | FLT1 (0.48) | KITBRAFFLT1KDRABL1 | |
| SCHEMBL4032272 | 0.87 | KIT (0.47) | KITBRAFFLT1KDR | |
| SCHEMBL4035614 | 0.84 | KIT (0.51) | KITBRAFFLT1KDR | |
| SCHEMBL4036546 | 0.83 | KIT (0.53) | KITBRAFFLT1KDR | |
| SCHEMBL13875588 | 0.82 | FLT1 (0.50) | KITBRAFFLT1KDRABL1 | |
| SCHEMBL3866845 | 0.82 | FLT1 (0.50) | KITBRAFFLT1KDRABL1 | |
| SCHEMBL4034467 | 0.82 | NPC1 (0.55) | KITBRAFFLT1KDRCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1392680-B1 | SELECTIVE ANTHRANILAMIDE PYRIDINE AMIDES AS INHIBITORS OF VEGFR-2 AND VEGFR-3 | BAYER SCHERING PHARMA AG (DE) | 2009-07-22 | — | — | EP | disclosed |
| US-20040254185-A1 | Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3 | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254185-A1 | Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3 | FLT4, KDR, FLT1 | KIT 34/4885BRAF 23/4885FLT1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.